Fewer than 60% of U.S. biopharma CEOs describe themselves as optimistic about the year ahead, according to a recent Deloitte survey. Among European and Asian counterparts, the figure is approximately 90%.
The drivers behind the gap are specific, not sentimental. Tariff threats on pharmaceutical imports remain unresolved. Individual companies have negotiated separate pricing arrangements directly with the federal government rather than operating under a single predictable policy. As of the end of August, 26 drugmakers now hold most-favored-nation pricing agreements with the administration, following a new round of nine companies added in a single announcement. FDA staffing instability, including senior departures and resignations, continues to affect review timelines and regulatory predictability. At the same time, M&A activity is rebounding, with 45% of executives naming dealmaking a priority and roughly half expecting new drug launches to strengthen their financial position — meaning the pessimism is concentrated in policy conditions, not in the underlying business.
The effect of this gap is not confined to boardroom sentiment. It shows up in succession planning.
In a recent CEO succession process for a U.S.-based biopharma company, the board’s leading external candidate — a sitting commercial leader at a European originator — raised a specific question before compensation was discussed: how the company planned to manage pricing-deal exposure and regulatory-timeline risk over a three-year horizon. The board could not yet answer with specificity. The candidate withdrew from the process within the week, citing insufficient clarity on how policy risk would be managed at the leadership level, not compensation or scope.
That is the more precise cost of the optimism gap. It is not primarily a communications problem or an investor-sentiment problem. It is increasingly a factor in whether the strongest external candidates are willing to take on U.S.-based leadership roles at all, and in whether sitting leaders view the mandate as one they can commit to for the long term.
Boards that treat policy-risk communication as solely a government-affairs function are underestimating its role in retention and succession. The organizations managing this well are building a clear, specific answer to “how are we navigating this” before it is asked in a search process — not during one.
How is your board addressing policy uncertainty as a leadership retention issue, rather than only a government-affairs issue?